Uveal Melanoma Trial Landscape (November 2026)

Last updated: Nov 22, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

33
Recruiting
15
Phase 1
17
Phase 2
6
Phase 3
0
Phase 4

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Looking for uveal melanoma trials matched to your specific case?

Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.

Find My Matches →

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Bispecific antibody
7
TIL cellular therapy
5
Checkpoint inhibitor
4
Small-molecule inhibitor
2
Other / unclassified
2
Antibody-drug conjugate (ADC)
1
Other inhibitor
1
Chemotherapy
1
CAR-T cellular therapy
1
Kinase inhibitor (other)
1

Recently Updated Trials

NCTPhaseTitleMechanism
NCT072033911Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisPI3Kdelta -- small molecule inhibitor (Roginolisib)
NCT070638751, 2Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionIL-2 -- cytokine immunotherapy (Aldesleukin)
NCT064145902Neoadjuvant Tebentafusp for Uveal Melanomagp100 peptide-HLA-A*0201 + T cell receptor -- bispecific T cell engager (ImmTAC)
NCT068058251A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kitc-Kit -- antibody-drug conjugate (NN3201)
NCT078041863Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaPKC (Protein Kinase C) -- kinase inhibitor (Darovasertib); ALK and MET -- kinase inhibitor (Crizotinib)

Top Sponsors

SponsorRecruiting trials
Vastra Gotaland Region3
H. Lee Moffitt Cancer Center and Research Institute3
University of Miami2
Thomas Jefferson University2
St Vincent's Hospital, Sydney2

Geographic Distribution

Countries/regions with the most active trial sites for uveal melanoma. A multi-site trial is counted once per country/region.

United States
19
Australia
7
United Kingdom
4
Spain
4
France
4
Sweden
3
Germany
3
Switzerland
2
Poland
2
Netherlands
2

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

StartNCTTitleMechanism
Jan 31, 2027NCT05903937Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesTumor infiltrating lymphocytes (TIL) -- adoptive cell therapy + alkylating agent (melphalan) + IL-2 -- cytokine
Jan 2027NCT07183852Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic MelanomaTumor-infiltrating lymphocytes + melphalan + IL-2 -- adoptive cell therapy + chemotherapy + cytokine
Jun 29, 2026NCT07501117Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaCTLA-4 + PD-1 -- immune checkpoint inhibitors (monoclonal antibodies)
Mar 2, 2026NCT07627698Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced MelanomaCSPG4 + GD2 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK)
Feb 1, 2026NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisPI3Kdelta -- small molecule inhibitor (Roginolisib)
Dec 3, 2025NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaCD40L + tumor antigens -- CD40L-augmented tumor infiltrating lymphocytes (cell therapy)

You've seen the uveal melanoma landscape. Now find the trials that fit your case.

Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.

Find My Matches →

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.